S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Centogene Stock Forecast, Price & News

-0.29 (-4.03%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
121,416 shs
Average Volume
54,262 shs
Market Capitalization
$137.23 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CNTG News and Ratings via Email

Sign-up to receive the latest news and ratings for Centogene and its competitors with MarketBeat's FREE daily newsletter.

Centogene logo

About Centogene

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.


See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$146.64 million
Book Value
$3.78 per share


Net Income
$-24.49 million
Pretax Margin




Free Float
Market Cap
$137.23 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.70 out of 5 stars

Medical Sector

915th out of 1,391 stocks

Medical Laboratories Industry

22nd out of 30 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Centogene (NASDAQ:CNTG) Frequently Asked Questions

Is Centogene a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Centogene in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Centogene stock.
View analyst ratings for Centogene
or view top-rated stocks.

How has Centogene's stock price been impacted by Coronavirus?

Centogene's stock was trading at $18.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CNTG stock has decreased by 63.2% and is now trading at $6.91.
View which stocks have been most impacted by COVID-19

When is Centogene's next earnings date?

Centogene is scheduled to release its next quarterly earnings announcement on Thursday, April 21st 2022.
View our earnings forecast for Centogene

How were Centogene's earnings last quarter?

Centogene (NASDAQ:CNTG) posted its quarterly earnings results on Wednesday, November, 24th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.59) by $0.49. Centogene had a negative trailing twelve-month return on equity of 50.71% and a negative net margin of 14.29%. During the same quarter last year, the firm posted ($0.32) EPS.
View Centogene's earnings history

What guidance has Centogene issued on next quarter's earnings?

Centogene issued an update on its FY 2021 earnings guidance on Wednesday, November, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $196.80 million-$211.94 million, compared to the consensus revenue estimate of $184.93 million.

What price target have analysts set for CNTG?

4 Wall Street analysts have issued twelve-month price targets for Centogene's stock. Their forecasts range from $14.00 to $24.00. On average, they expect Centogene's stock price to reach $19.00 in the next year. This suggests a possible upside of 175.0% from the stock's current price.
View analysts' price targets for Centogene
or view top-rated stocks among Wall Street analysts.

Who are Centogene's key executives?

Centogene's management team includes the following people:
  • Dr. Andrin Oswald Ph.D., M.D., Member of Management Board, CEO & MD (Age 49, Pay $540.62k)
  • Dr. Volkmar Weckesser Ph.D., Chief Information Officer & Member of Management Board (Age 53, Pay $918.82k)
  • Mr. Rene Just, Chief Financial Officer
  • Dr. Philip Lambert M.A., Ph.D., Chief Scientific Officer (Age 52)
  • Mr. Christoph de Artiagoitia, Sr. VP of Fin. & Admin.
  • Mr. Angelos Baxevanis, Sr. VP of Communication & Marketing
  • Mr. Robert W. de Deugd, Sr. VP of Sales
  • Ms. Nathalie Daste, Chief HR Officer
  • Mr. Sun Kim M.A., Ph.D., Chief Strategy Officer (Age 49)
  • Mr. Florian Vogel Ph.D., Chief Process Officer

What other stocks do shareholders of Centogene own?

When did Centogene IPO?

(CNTG) raised $60 million in an initial public offering (IPO) on Thursday, November 7th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Evercore ISI acted as the underwriters for the IPO and Baird and BTIG were co-managers.

What is Centogene's stock symbol?

Centogene trades on the NASDAQ under the ticker symbol "CNTG."

Who are Centogene's major shareholders?

Centogene's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Platinum Investment Management Ltd. (0.00%), Millennium Management LLC (2.51%), Renaissance Technologies LLC (0.28%) and Morgan Stanley (0.07%).

Which institutional investors are selling Centogene stock?

CNTG stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Morgan Stanley.

Which institutional investors are buying Centogene stock?

CNTG stock was acquired by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., and Millennium Management LLC.

How do I buy shares of Centogene?

Shares of CNTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Centogene's stock price today?

One share of CNTG stock can currently be purchased for approximately $6.91.

How much money does Centogene make?

Centogene has a market capitalization of $137.23 million and generates $146.64 million in revenue each year. The company earns $-24.49 million in net income (profit) each year or ($1.59) on an earnings per share basis.

How many employees does Centogene have?

Centogene employs 607 workers across the globe.

What is Centogene's official website?

The official website for Centogene is www.centogene.com.

Where are Centogene's headquarters?

Centogene is headquartered at AM STRANDE 7, ROSTOCK 2M, 18055.

How can I contact Centogene?

Centogene's mailing address is AM STRANDE 7, ROSTOCK 2M, 18055. The company can be reached via phone at 38180113500 or via email at [email protected].

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.